The USPSTF recommendations against PSA screening for prostate cancer have reduced screening and result in fewer diagnoses. Accountable Care Organizations (ACOs), which aim to improve population health and enhance financial stewardship, have the potential to accelerate the impact of such national recommendations. The extent to which ACOs translate such evidence into practice inevitably will determine their ability to improve value. In this context, we examined the effect of Medicare Shared Savings Program (MSSP) ACO participation on screening PSA tests and prostate biopsy.
INTRODUCTION AND OBJECTIVES:
The USPSTF recommendations against PSA screening for prostate cancer have reduced screening and result in fewer diagnoses. Accountable Care Organizations (ACOs), which aim to improve population health and enhance financial stewardship, have the potential to accelerate the impact of such national recommendations. The extent to which ACOs translate such evidence into practice inevitably will determine their ability to improve value. In this context, we examined the effect of Medicare Shared Savings Program (MSSP) ACO participation on screening PSA tests and prostate biopsy.
METHODS: We performed a retrospective cohort study using a 20% national Medicare sample to evaluate rates of PSA testing and prostate biopsy among men without prostate cancer between 2010 and 2014. Patients were aligned to ACOs based on MSSP alignment criteria. We measured secular trends over time and performed a difference-in-differences analysis to determine the causal effects of ACOs on rates of PSA testing and prostate biopsy by comparing outcomes in the post-implementation period to the pre-implementation period.
RESULTS: Among 1.1 million eligible men without prostate cancer, 144,109 (13.7%) were aligned to an ACO. In the non-ACO group we noted a 14% decrease in the annual rate of PSA testing and a 10% decrease in the annual rate of prostate biopsy (both p < 0.001). As shown in the Figure, ACOs had no effect beyond the secular trend on the rate of PSA testing (difference-in-differences estimator p¼0.11). However, ACOs accounted a slower decline in the rate of biopsies performed (difference-in-differences estimator p¼0.043).
CONCLUSIONS: Screening PSA testing and prostate biopsy rates decreased significantly over our study period. The rate of PSA testing, the decision for which is largely under the control of primary care physicians, was not affected by ACO participation. Conversely, the rate of prostate biopsy, the decision for which is under the control of urologists, resulted in a slower decrease in biopsy performance among ACO aligned men. Better engagement of ACOs with specialists is necessary for these organizations to achieve their objective.
Source of Funding: This work was supported by the American Cancer Society (RSG12-323-01-CPHPS), the National Cancer Institute (R01 CA168691, R01CA174768, T32 CA180984) and the National Institute on Aging (R01AG048071).
PD32-02 UNDERSTANDING PRE-ENROLLMENT FIRST YEAR COSTS OF UROLOGICAL CANCER CARE FOR HOSPITALS THAT WENT ON TO PARTICIPATE IN MEDICARE ACCOUNTABLE CARE ORGANIZATIONS
Deborah R. Kaye*, Hye Sung Min, Chad Ellimootil, Zaojun Ye, Jonathan Li, Lindsey A. Herrel, James M. Dupree, David C. Miller, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Accountable care organizations (ACOs) are a new delivery model that many believe will enhance care coordination and quality, while lowering costs, in patients with complex diagnoses like cancer. However, understanding the degree to which ACO participation improves outcomes depends on the performance of participants before they became ACOs. In this context, we measured and compared the total first year costs (i.e, initial phase) of urological cancer care among hospitals that did or did not enroll in the Medicare Shared Savings Program (MSSP) ACO.
METHODS: Using linked SEER-Medicare claims, we identified patients >65 years who were diagnosed with prostate, bladder, or kidney cancer from 2008 through 2012. The initial phase of cancer care was defined by the 12 months after diagnosis for patients living > 12 months. Costs of cancer care were calculated by aggregating hospital, physician and post-acute care claims. We first attributed patients to the hospital at which they received the majority of their initial cancer care. Hospitals were then flagged as ACO or non-ACO hospitals (based on current hospital participation) using the MSSP ACO Provider File. Finally, we compared total and component costs during the initial phase of cancer care according to ACO participation status.
RESULTS: We identified 64,879 patients with prostate cancer, 19,554 patients with bladder and 9,484 patients with kidney cancer. The proportion of patients receiving care at a hospital that subsequently enrolled in the ACO program was 4%, 5%, and 5% for prostate, bladder, and kidney cancer, respectively. Prior to the initiation of the ACO program, patients attributed to current ACO hospitals had lower aggregate first year costs for prostate (p<0.001) and kidney cancer (p<0.001), but not bladder cancer (p¼0.938). Differences in inpatient spending were +$305, +$1,245, and -$1,535 for prostate, bladder and kidney cancer, respectively ( Figure) .
CONCLUSIONS: Prior to formal participation, patients treated at hospitals now enrolled in the MSSP ACO program had lower costs for the first 12 months after diagnosis for prostate and kidney cancer, but not bladder cancer. Evaluations of the impact of ACO participation on costs of urologic cancer care may therefore be most fruitful among patients with bladder cancer.
INTRODUCTION AND OBJECTIVES:
Prostate cancer is the most common and among the most costly cancer in US men. Uncertainties regarding optimal management lead to treatment variations and increase cost. Accountable care organizations (ACO) can potentially improve care by decreasing variation (i.e. avoidance of treatment in low value settings) and constraining costs. Our objective was to determine the effect of Medicare Shared Savings Program (MSSP) ACOs on prostate cancer care.
METHODS: Using a 20% Medicare sample we perform a retrospective cohort study of men with newly diagnosed prostate cancer from 2010-2013. We assigned patients to ACOs based on their primary care provider's MSSP ACO participation. We then performed a difference-in-differences analysis comparing the impact of ACO participation on initial prostate cancer curative treatment, treatment of men with a very high 10-year non-cancer mortality risk (i.e. those least likely to benefit) and per beneficiary payments. Outcomes in the post-implementation period were compared to outcomes in the preimplementation.
RESULTS: We identified 33,461 men with incident prostate cancer of which 5,015 (15%) were assigned to an ACO. Overall, 58% of men were diagnosed in the pre-ACO implementation period. We noted secular trends in the non-ACO group from pre-to post-implementation in overall curative treatment (4.2% decline, p<0.001), treatment of men with the highest non-cancer mortality risk (6.2% increase, p¼0.11) and annual per beneficiary payments 4.0% decrease (p<0.001). ACO participation had no significant effect beyond the secular trend (Figure) on overall treatment or annual payments (difference-in-differences estimator p¼0.8, p¼0.09, respectively). There was a significant relative decrease in treatment among men with the highest mortality risk of 17% (p¼0.03), however did this not lead to differences in cost.
CONCLUSIONS: Curative treatment of prostate cancer and annual per beneficiary payments decreased significantly between 2010 and 2013. For men diagnosed with prostate cancer, ACO participation did not impact trends in treatment or cost. However, among men least likely to benefit, ACOs resulted in a decline in treatment of prostate cancer.
Source of Funding: This work was supported by the American Cancer Society (RSG 12-323-01-CPHPS), the National Cancer Institute (R01 CA168691, R01 CA174768, T32 CA180984) and the National Institute on Aging (R01 AG048071).
PD32-04 SURGEON ENGAGEMENT IN EARLY ACCOUNTABLE CARE ORGANIZATIONS
Matthew Resnick*, Amy Graves, Melinda Buntin, Michael Richards, David Penson, Nashville, TN INTRODUCTION AND OBJECTIVES: Despite marked growth in Accountable Care Organizations (ACOs), little is known about either the magnitude of surgeon engagement or key drivers of surgeon engagement in early ACO programs. We aimed to characterize the landscape of surgeon engagement in early ACOs and identify specialty-, organization-, and market-factors associated with early ACO participation.
METHODS: Using data from SK&A, a commercial research firm, we evaluated independent, group, and integrated U.S. surgical practices, performing a cross-sectional analysis of 2015 ACO enrollment among 125,425 U.S. surgeons. We fit a multivariable logistic regression model to evaluate associations between ACO affiliation, surgical specialty, and organizational structure while adjusting for surgeon characteristics.
RESULTS: Of 125,425 U.S. surgeons, 27,956 (22.3%) reported enrollment in at least 1 ACO program in 2015. We identified significant heterogeneity in the proportion of ACO-enrolled surgeons by surgical specialty, with trauma and transplant reporting the highest magnitude of ACO enrollment, (36% for both) and plastic surgeons reported the lowest magnitude of ACO enrollment (12.9%) followed by ophthalmology (16.0%) and hand (18.6%). 22.8% of urologists reported at least 1 ACO contract. Practice organization was strongly associated with ACO enrollment, with surgeons in group practices and integrated health systems had higher odds of ACO affiliation relative to those practicing independently (aOR 1.57, 95% CI 1.50, 1.64; aOR 4.87, 95% CI 4.68, 5.07, respectively). We observed a statistically significant interaction (p<0.001) between surgical specialty and practice organization. Modelderived predicted probabilities revealed that, within each specialty, surgeons in an integrated health system had the highest predicted probabilities of ACO affiliation while those practicing in groups had smaller predicted probabilities and those practicing independently generally had the lowest. This pattern was largely consistent across surgical specialties. CONCLUSIONS: We observed considerable variation in ACO enrollment among U.S. surgeons. Observed variation appears to be largely mediated by differences in practice organization, with surgeons practicing in integrated health systems more likely to engage in ACO contracts than those in independent practice.
